Crucell receives underperform rating from Jefferies

Jefferies International Ltd. gave Crucell an underperform rating. Crucell secured a strategic agreement with sanofi-aventis to develop pandemic and seasonal influenza vaccines and has West Nile Virus and Ebola vaccines in the pipeline, but Jefferies analyst Nick Turner predicted the company's third-quarter numbers on Oct. 17 will reveal revenues of €5.6 million, a net loss of €7.8 million, or €0.19 per share.

"In our opinion, all programs at Crucell carry significant development risk," said Turner.

Shares of the biopharmaceutical company, based in Leiden, the Netherlands, were down $1.34, or 4.92%, at $25.91 on volume of 752,529 shares versus the three-month running average of 213,568 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.